Quick Answer
Climb Bio, Inc. reported Stockholders Equity of $160.48 million for the year ending 2025.
- Climb Bio, Inc. showed a decrease of -24.3% in Stockholders Equity from 2024 to 2025.
- This data is from Climb Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$7.78 million | Q2 2020: -$9.82 million | Q3 2020: -$12.49 million | Q1 2021: -$43.18 million | Q2 2021: -$50.85 million | Q3 2021: $176.66 million | Q1 2022: $155.14 million | Q2 2022: $142.24 million | Q3 2022: $134.36 million | Q1 2023: $116.86 million | Q2 2023: $112.50 million | Q3 2023: $109.74 million | Q1 2024: $106.38 million | Q2 2024: $222.28 million | Q3 2024: $218.78 million | Q1 2025: $193.39 million | Q2 2025: $185.76 million | Q3 2025: $177.00 million.
- Over the full 7 years of available data (2019 to 2025), Climb Bio, Inc.'s Stockholders Equity has grown by 2,985.2%.
- Historical annual values: Fiscal year 2025: $160.48 million | Fiscal year 2024: $211.88 million | Fiscal year 2023: $107.60 million | Fiscal year 2022: $128.72 million | Fiscal year 2021: $167.20 million | Fiscal year 2020: -$24.98 million | Fiscal year 2019: -$5.56 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: